Assay (CP-GEP) in melanoma care
Source: PR Newswire, October 2023
ROTTERDAM, Netherlands and SAN DIEGO, Oct. 31, 2023 /PRNewswire/ — SkylineDx an innovative diagnostics company focused on research & development of molecular diagnostics for oncology and inflammatory diseases, proudly announces the successful clinical validation and implementation of the clinicopathologic and gene expression profile (CP-GEP) model in a multicenter Dutch study focused on patients with melanoma.
The study, titled “Clinical Evaluation of the Clinicopathologic and Gene Expression Profile (CP-GEP) in Patients with Melanoma Eligible for Sentinel Lymph Node Biopsy: A Multicenter Prospective Dutch Study," [1] aimed to evaluate the clinical use and implementation of the CP-GEP model in a prospective multicenter study in the Netherlands.
Melanoma, a highly aggressive form of skin cancer, often necessitates sentinel lymph node biopsy (SLNB) for staging, prognostication, and determining eligibility for adjuvant therapy. However, the majority of SLNB procedures do not reveal nodal metastasis, exposing patients to unnecessary surgeries and potential complications.